Comment from Americans for Scientific Integrity

Petitioner respectfully submits for inclusion in the administrative record the following newly published study: Herrington et al. (2026), “Two-Hit Exposure to Lipopolysaccharide and Acetaminophen Alters Larval Zebrafish (Danio rerio) Swim Behavior.” This experimental study is notable because it directly models a “two-hit” framework in which early-life inflammation is followed by acetaminophen exposure, a sequence that closely mirrors real-world pediatric use, where acetaminophen is most commonly administered during fever, infection, or other inflammatory states. The authors report that acetaminophen exposure altered neurobehavioral outcomes in developing zebrafish and, importantly, that combined exposure to inflammation and acetaminophen produced interaction effects on behavior that were not fully explained by either exposure alone, including changes in activity and lateralized movement patterns. While the findings are modest, derived from an animal model, and do not establish causation in humans, the study is highly relevant from a regulatory perspective because it addresses a key limitation of the existing literature: most prior studies evaluate acetaminophen in isolation rather than in the biologically realistic context in which it is actually used. The authors themselves emphasize that this context is critical, noting that inflammation and illness are independently associated with neurodevelopmental risk and may interact with drug exposure. Accordingly, this study provides additional mechanistic and experimental support for the plausibility of a context-dependent risk model, in which acetaminophen exposure during periods of immune activation may have different developmental effects than exposure in a non-inflamed state. Petitioner does not contend that this study is dispositive on its own, but rather that it strengthens the overall evidentiary record by demonstrating that inflammatory context is not merely a confounder but may be an integral component of risk. For this reason, the study is directly relevant to the requested pediatric warning and should be included in the FDA’s evaluation of whether current labeling adequately reflects real-world conditions of use and potential susceptibility in early childhood.